Advertisement

Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis

Published:October 05, 2018DOI:https://doi.org/10.1016/j.ejca.2018.08.016

      Highlights

      • The pharmacotherapy for chronic myeloid leukaemia is tyrosine kinase inhibitors (TKIs).
      • Systematic review and network meta-analysis were performed including randomised controlled trial that evaluated the use of TKI.
      • We built six networks, one for each of the outcomes under analysis.
      • The findings showed a beneficial effect of therapy with nilotinib compared with other drugs.

      Abstract

      Background

      The pharmacotherapy of chronic myeloid leukaemia (CML) is mainly based on tyrosine kinase inhibitors (TKIs). The aim of this study was to compare the efficacy and safety of all TKIs in CML patients.

      Methods

      We conducted a systematic review with network meta-analysis (NMA) of randomised controlled trials (RCTs), including imatinib, nilotinib, dasatinib, bosutinib, radotinib and ponatinib. Searches were performed in PubMed, Scopus, Web of Science and SciELo (March 2018). The NMAs were built for six outcomes at 12 months: complete cytogenetic response (CCyR), major cytogenetic response (MCyR), deep molecular response, major molecular response (MMR), complete haematologic response and incidence of serious adverse events. We conducted rank order and surface under the cumulative ranking curve (SUCRA) analyses.

      Results

      Thirteen RCTs were included (n = 5079 patients). Statistical differences were observed for some comparisons in all outcomes. Imatinib 400 mg was considered the safest drug (SUCRA values of 10.3%) but presented low efficacy. Overall, nilotinib 600 mg was superior to the other TKI in efficacy (SUCRA values of 61.1% for CCyR, 81.0% for MMR, 90.0% for MCyR); however, no data on its safety profile at 12 months were reported.

      Interpretation

      Our results suggest that nilotinib should be upgraded to first-line therapy for CML, although further cost-effectiveness analyses, including the new TKI (i.e., ponatinib, radotinib), are needed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hoglund M.
        • Sandin F.
        • Simonsson B.
        Epidemiology of chronic myeloid leukaemia: an update.
        Ann Hematol. 2015; 94: S241-S247
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2017.
        CA A Cancer J Clin. 2017; 67: 7-30
        • Rowley J.D.
        Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
        Nature. 1973; 243: 290-293
        • Shah K.
        • Parikh S.
        • Rawal R.
        Tyrosine kinase inhibitors in Ph+ chronic myeloid leukemia therapy: a review.
        Asian Pac J Cancer Prev: APJCP. 2016; 17: 3025-3033
        • Kantarjian H.M.
        • O'Brien S.
        • Cortes J.
        • Giles F.J.
        • Rios M.B.
        • Shan J.
        • et al.
        Imatinib mesylate therapy improves survival in patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
        Cancer. 2003; 98: 2636-2642
        • O'Brien S.G.
        • Guilhot F.
        • Larson R.A.
        • Gathmann I.
        • Baccarani M.
        • Cervantes F.
        • et al.
        Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
        N Engl J Med. 2003; 348: 994-1004
        • Baccarani M.
        • Saglio G.
        • Goldman J.
        • Hochhaus A.
        • Simonsson B.
        • Appelbaum F.
        • et al.
        Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
        Blood. 2006; 108: 1809-1820
        • Network
        NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia version 2.
        NCC, 2018: 2017
        • Baccarani M.
        • Castagnetti F.
        • Gugliotta G.
        • Rosti G.
        A review of the European LeukemiaNet recommendations for the management of CML.
        Ann Hematol. 2015; 94: S141-S147
        • Cortes J.E.
        • Kantarjian H.M.
        • Brummendorf T.H.
        • Kim D.W.
        • Turkina A.G.
        • Shen Z.X.
        • et al.
        Safety and efficacy of bosutinib (SKI-606) in chronic phase philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
        Blood. 2011; 118: 4567-4576
        • Cortes J.E.
        • Khoury H.J.
        • Kantarjian H.M.
        • Lipton J.H.
        • Kim D.W.
        • Schafhausen P.
        • et al.
        Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
        Am J Hematol. 2016; 91: 1206-1214
        • Cortes J.E.
        • Kim D.W.
        • Pinilla-Ibarz J.
        • le Coutre P.
        • Paquette R.
        • Chuah C.
        • et al.
        A phase 2 trial of ponatinib in philadelphia chromosome-positive leukemias.
        N Engl J Med. 2013; 369: 1783-1796
        • Kantarjian H.M.
        • Ibarz J.P.
        • Le Coutre P.D.
        • Paquette R.
        • Chuah C.
        • Nicolini F.E.
        Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).
        J Clin Oncol. 2017; 35: 7012
        • Alikian M.
        • Gale R.P.
        • Apperley J.F.
        • Foroni L.
        Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
        Biomol Detect Quantification. 2017; 11: 4-20
        • Jansen J.P.
        • Naci H.
        Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers.
        BMC Med. 2013; 11: 159
        • Mealing S.
        • Barcena L.
        • Hawkins N.
        • Clark J.
        • Eaton V.
        • Hirji I.
        • et al.
        The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis.
        Exp Hematol Oncol. 2013; 2: 5
        • Signorovitch J.
        • Ayyagari R.
        • Reichmann W.M.
        • Wu E.Q.
        • Chen L.
        Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
        Cancer Treat Rev. 2014; 40: 285-292
        • Hutton B.
        • Salanti G.
        • Caldwell D.M.
        • Chaimani A.
        • Schmid C.H.
        • Cameron C.
        • et al.
        The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.
        Ann Intern Med. 2015; 162: 777-784
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        J Clin Epidemiol. 2009; 62: 1006-1012
        • Higgins J.P.T.
        • Green S.
        Cochrane handbook for systematic reviews of interventions version 5.1.0.
        Cochrane, 2011
        • Jadad A.R.
        • Moore R.A.
        • Carroll D.
        • Jenkinson C.
        • Reynolds D.J.
        • Gavaghan D.J.
        • et al.
        Assessing the quality of reports of randomized clinical trials: is blinding necessary?.
        Control Clin Trials. 1996; 17: 1-12
        • Tonin F.S.
        • Rotta I.
        • Mendes E.M.
        • Pontarolo R.
        Network meta-analysis: a technique to gather evidence from direct and indirect comparisons.
        Pharm Pract (Granada). 2017; 15: 943
        • Hoaglin D.C.
        • Hawkins N.
        • Jansen J.P.
        • Scott D.A.
        • Itzler R.
        • Cappelleri J.C.
        • et al.
        Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 2.
        Value Health. 2011; 14: 429-437
        • Jansen J.P.
        • Fleurence R.
        • Devine B.
        • Itzler R.
        • Barrett A.
        • Hawkins N.
        • et al.
        Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1.
        Value Health. 2011; 14: 417-428
        • Dias S.
        • Sutton A.J.
        • Ades A.E.
        • Welton N.J.
        Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials.
        Med Decis Making. 2013; 33: 607-617
        • Lu G.
        • Ades A.E.
        Combination of direct and indirect evidence in mixed treatment comparisons.
        Stat Med. 2004; 23: 3105-3124
        • Mbuagbaw L.
        • Rochwerg B.
        • Jaeschke R.
        • Heels-Andsell D.
        • Alhazzani W.
        • Thabane L.
        • et al.
        Approaches to interpreting and choosing the best treatments in network meta-analyses.
        Syst Rev. 2017; 6: 79
        • Van Valkenhoef G.
        • Dias S.
        • Ades A.E.
        • Welton N.J.
        Automated generation of node splitting models for assessment of inconsistency in network meta-analysis.
        Res Synth Meth. 2015; 7: 80-93
        • Dias S.
        • Welton N.J.
        • Caldwell D.M.
        • Ades A.E.
        Checking consistency in mixed treatment comparison meta-analysis.
        Stat Med. 2010; 29: 932-944
        • Veroniki A.A.
        • Vasiliadis H.S.
        • Higgins J.P.
        • Salanti G.
        Evaluation of inconsistency in networks of interventions.
        Int J Epidemiol. 2013; 42: 332-345
        • Van Valkenhoef G.
        • Lu G.
        • Brock B.
        • Hillege H.
        • Ades A.E.
        • Welton N.J.
        Automating network meta-analysis.
        Res Synth Meth. 2012; 3: 285-299
        • Baccarani M.
        • Rosti G.
        • Castagnetti F.
        • Haznedaroglu I.
        • Porkka K.
        • Abruzzese E.
        • et al.
        Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.
        Blood. 2009; 113: 4497-4504
        • Cortes J.E.
        • Baccarani M.
        • Guilhot F.
        • Druker B.J.
        • Branford S.
        • Kim D.W.
        • et al.
        Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
        J Clin Oncol. 2010; 28: 424-430
        • Cortes J.E.
        • Kim D.W.
        • Kantarjian H.M.
        • Brummendorf T.H.
        • Dyagil I.
        • Griskevicius L.
        • et al.
        Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
        J Clin Oncol. 2012; 30: 3486-3492
        • Cortes J.E.
        • Gambacorti-Passerini C.
        • Deininger M.W.
        • Mauro M.J.
        • Chuah C.
        • Kim D.W.
        • et al.
        Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial.
        J Clin Oncol. 2017; (JCO2017747162): 1-7
        • Deininger M.W.
        • Kopecky K.J.
        • Radich J.P.
        • Kamel-Reid S.
        • Stock W.
        • Paietta E.
        • et al.
        Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
        Br J Haematol. 2014; 164: 223-232
        • Hehlmann R.
        • Lauseker M.
        • Jung-Munkwitz S.
        • Leitner A.
        • Müller M.C.
        • Pletsch N.
        • et al.
        Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
        J Clin Oncol. 2011; 29: 1634-1642
        • Hehlmann R.
        • Lauseker M.
        • Saussele S.
        • Pfirrmann M.
        • Krause S.
        • Kolb H.J.
        • et al.
        Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
        Leukemia. 2017; 31: 2398-2406
        • Hjorth-Hansen H.
        • Stenke L.
        • Soderlund S.
        • Dreimane A.
        • Ehrencrona H.
        • Gedde-Dahl T.
        • et al.
        Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
        Eur J Haematol. 2015; 94: 243-250
        • Kantarjian H.
        • Shah N.P.
        • Hochhaus A.
        • Cortes J.
        • Shah S.
        • Ayala M.
        • et al.
        Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
        N Engl J Med. 2010; 362: 2260-2270
        • Kwak J.Y.
        • Kim S.H.
        • Oh S.J.
        • Zang D.Y.
        • Kim H.
        • Kim J.A.
        • et al.
        Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia.
        Clin Canc Res. 2017; 23: 7180-7188
        • Lipton J.H.
        • Chuah C.
        • Guerci-Bresler A.
        • Rosti G.
        • Simpson D.
        • Assouline S.
        • et al.
        Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
        Lancet Oncol. 2016; 17: 612-621
        • Radich J.P.
        • Kopecky K.J.
        • Appelbaum F.R.
        • Kamel-Reid S.
        • Stock W.
        • Malnassy G.
        • et al.
        A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
        Blood. 2012; 120: 3898-3905
        • Saglio G.
        • Kim D.W.
        • Issaragrisil S.
        • Le Coutre P.
        • Etienne G.
        • Lobo C.
        • et al.
        Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
        N Engl J Med. 2010; 362: 2251-2259
        • Wang J.
        • Shen Z.X.
        • Saglio G.
        • Jin J.
        • Huang H.
        • Hu Y.
        • et al.
        Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
        Blood. 2015; 125: 2771-2778
        • Bennour A.
        • Saad A.
        • Sennana H.
        Chronic myeloid leukemia: relevance of cytogenetic and molecular assays.
        Crit Rev Oncol Hematol. 2016; 97: 263-274
        • Jabbour E.
        • Kantarjian H.
        Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
        Am J Hematol. 2016; 91: 252-265
        • Vardiman J.W.
        Chronic myelogenous leukemia, BCR-ABL1+.
        Am J Clin Pathol. 2009; 132: 250-260
        • Bauer S.
        • Romvari E.
        Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia.
        J Adv Pract Oncol. 2012; 3: 151-160
        • Press R.D.
        Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.
        Oncol. 2010; 15: 744-749
        • Kantarjian H.
        • Schiffer C.
        • Jones D.
        • Cortes J.
        Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
        Blood. 2008; 111: 1774-1780
        • Hughes T.
        • Deininger M.
        • Hochhaus A.
        • Branford S.
        • Radich J.
        • Kaeda J.
        • et al.
        Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
        Blood. 2006; 108: 28-37
        • Baccarani M.
        • Soverini S.
        • De Benedittis C.
        Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
        in: American society of clinical oncology educational book American society of clinical oncology meeting. 2014: 167-175
        • Network N.C.C.
        NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia version 1. 2016. 2016
        • Vinhas R.
        • Cordeiro M.
        • Pedrosa P.
        • Fernandes A.R.
        • Baptista P.V.
        Current trends in molecular diagnostics of chronic myeloid leukemia.
        Leuk Lymphoma. 2017; 58: 1791-1804
        • Dulucq S.
        • Mahon F.X.
        Deep molecular responses for treatment-free remission in chronic myeloid leukemia.
        Cancer Med. 2016; 5: 2398-2411
        • Hughes T.M.
        • Ross D.M.
        Moving treatment-free remission into mainstream clinical practice in CML.
        Blood. 2016; 128: 17-23
        • Cortes J.E.
        • Kantarjian H.
        • Shah N.P.
        • Bixby D.
        • Mauro M.J.
        • Flinn I.
        • et al.
        Ponatinib in refractory philadelphia chromosome-positive leukemias.
        N Engl J Med. 2012; 367: 2075-2088
        • Goldman J.M.
        Ponatinib for chronic myeloid leukemia.
        N Engl J Med. 2012; 367: 2148-2149
        • Hoy S.M.
        Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
        Drugs. 2014; 74: 793-806
        • Dorer D.J.
        • Knickerbocker R.K.
        • Baccarani M.
        • Cortes J.E.
        • Hochhaus A.
        • Talpaz M.
        • et al.
        Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients.
        Leuk Res. 2016; 48: 84-91
        • O'Hare T.
        • Zabriskie M.S.
        • Eiring A.M.
        • Deininger M.W.
        Pushing the limits of targeted therapy in chronic myeloid leukaemia.
        Nat Rev Canc. 2012; 12: 513-526
        • Pagnano K.B.
        • Bendit I.
        • Boquimpani C.
        • De Souza C.A.
        • Miranda E.C.
        • Zalcberg I.
        • et al.
        BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
        Cancer Invest. 2015; : 1-8
        • Awidi A.
        • Ababneh N.
        • Magablah A.
        • Bsoul N.
        • Mefleh R.
        • Marei L.
        • et al.
        ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.
        Genet Test Mol Biomarkers. 2012; 16: 1317-1321
        • Douxfils J.
        • Haguet H.
        • Mullier F.
        • Chatelain C.
        • Graux C.
        • Dogne J.M.
        Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis.
        JAMA Oncol. 2016; : E1-E8
        • Fava C.
        • Saglio G.
        Ponatinib for chronic myeloid leukaemia: future perspectives.
        Lancet Oncol. 2016; 17: 546-547
        • Haguet H.
        • Douxfils J.
        • Mullier F.
        • Chatelain C.
        • Graux C.
        • Dogne J.M.
        Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
        Expet Opin Drug Saf. 2017; 16: 5-12
        • Jain P.
        • Kantarjian H.
        • Jabbour E.
        • Gonzalez G.N.
        • Borthakur G.
        • Pemmaraju N.
        • et al.
        Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.
        Lancet Haematol. 2015; 2: e376-e383
        • Blay J.Y.
        • von Mehren M.
        Nilotinib: a novel, selective tyrosine kinase inhibitor.
        Semin Oncol. 2011; 38: S3-S9
        • Swords R.
        • Mahalingam D.
        • Padmanabhan S.
        • Carew J.
        • Giles F.
        Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.
        Drug Des Dev Ther. 2009; 3: 89-101
        • Vaid A.
        Nilotinib as first-line therapy for chronic myeloid leukemia.
        Indian J Cancer. 2011; 48: 438-445
        • Piccaluga P.P.
        • Paolini S.
        • Bertuzzi C.
        • De Leo A.
        • Rosti G.
        First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation.
        Hematol Res Rev. 2012; 3: 151-156
        • Emole J.
        • Talabi T.
        • Pinilla-Ibarz J.
        Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib.
        Biol Targets Ther. 2016; 10: 23-31
        • An X.
        • Tiwari A.K.
        • Sun Y.
        • Ding P.R.
        • Ashby Jr., C.R.
        • Chen Z.S.
        BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
        Leuk Res. 2010; 34: 1255-1268
        • Jabbour E.
        • Kantarjian H.
        • Cortes J.
        Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
        Clin Lymphoma Myeloma Leukemia. 2015; 15: 323-334
        • Yun S.
        • Vincelette N.D.
        • Segar J.M.
        • Dong Y.
        • Shen Y.
        • Kim D.W.
        • et al.
        Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups: a systematic review and meta-analysis of eight randomized trials.
        Clin Lymphoma Myeloma Leukemia. 2016; 16: e85-e94
        • Breccia M.
        • Alimena G.
        Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.
        Leuk Res. 2010; 34: 129-134
        • Jabbour E.
        • Saglio G.
        • Radich J.
        • Kantarjian H.
        Adherence to BCR-ABL inhibitors: issues for CML therapy.
        Clinical lymphoma, myeloma & leukemia. 2012; 12: 223-229
        • Ibrahim A.R.
        • Eliasson L.
        • Apperley J.F.
        • Milojkovic D.
        • Bua M.
        • Szydlo R.
        • et al.
        Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.
        Blood. 2011; 117: 3733-3736
        • Marin D.
        • Bazeos A.
        • Mahon F.X.
        • Eliasson L.
        • Milojkovic D.
        • Bua M.
        • et al.
        Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
        J Clin Oncol. 2010; 28: 2381-2388
        • Noens L.
        • van Lierde M.A.
        • De Bock R.
        • Verhoef G.
        • Zachee P.
        • Berneman Z.
        • et al.
        Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
        Blood. 2009; 113: 5401-5411
        • de Almeida M.H.
        • Fogliatto L.
        • Couto D.
        Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia.
        Rev Bras Hematol Hemoter. 2014; 36: 54-59
        • Wu E.Q.
        • Guerin A.
        • Yu A.P.
        • Bollu V.K.
        • Guo A.
        • Griffin J.D.
        Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
        Curr Med Res Opin. 2010; 26: 2861-2869
        • Yood M.U.
        • Oliveria S.A.
        • Cziraky M.
        • Hirji I.
        • Hamdan M.
        • Davis C.
        Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
        Curr Med Res Opin. 2012; 28: 213-219
        • Bixby D.
        • Talpaz M.
        Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
        Hematol Am Soc Hematol Educ Progr. 2009; : 461-476
        • Lamontanara A.J.
        • Gencer E.B.
        • Kuzyk O.
        • Hantschel O.
        Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
        Biochim Biophys Acta. 2013; 1834: 1449-1459
        • Bhamidipati P.K.
        • Kantarjian H.
        • Cortes J.
        • Cornelison A.M.
        • Jabbour E.
        Management of imatinib-resistant patients with chronic myeloid leukemia.
        Therapeut Adv Hematol. 2013; 4: 103-117
        • Zhang W.W.
        • Cortes J.E.
        • Yao H.
        • Zhang L.
        • Reddy N.G.
        • Jabbour E.
        • et al.
        Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
        J Clin Oncol. 2009; 27: 3642-3649
        • Zabriskie M.S.
        • Vellore N.A.
        • Gantz K.C.
        • Deininger M.W.
        • O'Hare T.
        Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.
        Leukemia. 2015; 29: 1939-1942
        • Fuerst M.L.
        In CML: radotinib as frontline therapy; ponatinib promising for T315I patients.
        in: American society of hematology annual meeting. 2016: 30-31
        • Kim S.H.
        • Menon H.
        • Jootar S.
        • Saikia T.
        • Kwak J.Y.
        • Sohn S.K.
        • et al.
        Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
        Haematologica. 2014; 99: 1191-1196
        • Jabbour E.
        Chronic myeloid leukemia: first-line drug of choice.
        Am J Hematol. 2016; 91: 59-66
        • Hochhaus A.
        • Larson R.A.
        • Guilhot F.
        • Radich J.P.
        • Branford S.
        • Hughes T.P.
        • et al.
        Long-term outcomes of imatinib treatment for chronic myeloid leukemia.
        N Engl J Med. 2017; 376: 917-927
        • Hochhaus A.
        • Saglio G.
        • Hughes T.P.
        • Larson R.A.
        • Kim D.W.
        • Issaragrisil S.
        • et al.
        Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
        Leukemia. 2016; 30: 1044-1054
        • Shah N.P.
        • Rousselot P.
        • Schiffer C.
        • Rea D.
        • Cortes J.E.
        • Milone J.
        • et al.
        Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
        Am J Hematol. 2016; 91: 869-874
        • Shah N.P.
        • Guilhot F.
        • Cortes J.E.
        • Schiffer C.A.
        • le Coutre P.
        • Brummendorf T.H.
        • et al.
        Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
        Blood. 2014; 123: 2317-2324
        • Cortes J.E.
        • Saglio G.
        • Kantarjian H.M.
        • Baccarani M.
        • Mayer J.
        • Boque C.
        • et al.
        Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial.
        J Clin Oncol. 2016; 34: 2333-2340
        • Cortes J.E.
        • Kim D.W.
        • Pinilla-Ibarz J.
        • le Coutre P.D.
        • Paquette R.
        • Chuah C.
        • et al.
        Ponatinib efficacy and safety in philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
        Blood. 2018; 36: 231-237
        • Gambacorti-Passerini C.
        • Cortes J.E.
        • Lipton J.H.
        • Kantarjian H.M.
        • Kim D.W.
        • Schafhausen P.
        • et al.
        Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.
        Haematologica. 2018; 103: 1298-1307
        • Chen C.T.
        • Kesselheim A.S.
        Journey of generic imatinib: a case study in oncology drug pricing.
        J Oncol Pract. 2017; 13: 352-355